Biologics Prescribers Collaborative

What Biologics Prescribers Collaborative does

The Biologics Prescribers Collaborative (BPC) is a Washington, D.C.-based nonprofit advocacy coalition that provides educational resources and policy advocacy to help prescribers make informed decisions about biologics and biosimilar medicines. It is co-convened by four physicians — Dennis R. Cryer, MD; Gregory Schimizzi, MD; David Charles, MD (also Founder of Alliance for Patient Access); and Arturo Loaiza-Bonilla, MD — and operates as a coalition of eight medical specialty societies covering rheumatology, gastroenterology, endocrinology, allergy/asthma, neurology, and rheumatology nursing. The organization does not sell products or services; its core offerings are educational content (Biologics & Biosimilars 101, the Biosimilars Pathway 101, the Biosimilar Promise handbook, disease-specific fact sheets), policy papers on issues such as Medicare Part B negotiation, insurance design, and non-medical switching, and an annual National Policy & Advocacy Summit on Biologics now in its seventh iteration.

BPC's underlying technology is a content and education platform (website biologicsprescribers.org) with no proprietary software, API, or AI capabilities — its distribution is built on a content-marketing model across email newsletters, Twitter (@bioprescribers), downloadable PDFs, one-pagers, and event programming. The business model is coalition-based advocacy, not commercial: there is no pricing model, no disclosed revenue, no investors, no funding rounds, and no headcount data. The organization is funded through its member-society structure and co-convening relationship with Alliance for Patient Access, and its primary outputs are policy influence, prescriber education, and patient-facing resources rather than revenue-generating products. Its geographic focus is the United States, with no global footprint claim, and its stakeholders are healthcare providers, patient advocates, and healthcare policy stakeholders.

Name

Biologics Prescribers Collaborative

Legal name

Biologics Prescribers Collaborative

Website

https://biologicsprescribers.org

Company type

Private

Operating status

Operating

Short description

Biologics Prescribers Collaborative is a nonprofit advocacy coalition of medical specialty societies that provides educational resources and policy advocacy to help prescribers, patient advocates, and policy stakeholders make informed decisions about biologics and biosimilars.

Ownership category

akta.pro rank

Product category

Healthcare Policy Advocacy

SIC

Services-Health Services (8000)

akta.pro primary industry

Biologics & Vaccine Regulators (HLAJADAB)

akta.pro secondary industry

Clinical Trials Authorization & Oversight (GCP) (HLAJADAF)

Keywords

• Biologics policy education
• Biosimilars advocacy
• Prescriber coalition
• Healthcare policy resources
• Biologics market development

Headquarters

HQ city

Washington

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Distribution channels1 record

Marketing channels5 records

Core offering

The Biologics Prescribers Collaborative provides educational resources, policy papers, disease-specific fact sheets, patient guides, and an annual policy summit to inform healthcare prescribers and policy stakeholders about biologics and biosimilars. It functions as a coalition of medical specialty societies offering a unified prescriber voice on biologics policy, rather than selling commercial products or services.

Product overview

Biologics Prescribers Collaborative (BPC) is an advocacy coalition focused on ensuring sound policies for the safest possible use of all biologics, including biosimilars, for all patients. The organization does not offer a commercial software product but rather provides a portfolio of educational resources, policy papers, and convening services. The core offerings include foundational educational resources (Biologics & Biosimilars 101, The Biosimilars Pathway 101), disease-specific fact sheets covering therapeutic areas such as oncology, gastroenterology, and endocrinology, annual policy summits (National Policy & Advocacy Summit on Biologics), and patient education guides. BPC functions as a convening body bringing together healthcare providers, policy experts, and patient advocates rather than as a product company.

Differentiator

Problem solved

Functional benefit

Products and services

• Biologics & Biosimilars 101

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eight partnerships are on record, tiered core.

• Alliance for Patient AccesscoreStrategic or Co-development PartnerCo-convening organization of the Biologics Prescribers Collaborative. David Charles, MD serves as Founder of Alliance for Patient Access and Co-convenor of BPC.
• American College of Allergy Asthma and ImmunologycoreStrategic or Co-development PartnerMember organization of the Biologics Prescribers Collaborative coalition
• American College of RheumatologycoreStrategic or Co-development PartnerMember organization of the Biologics Prescribers Collaborative coalition
• American Gastroenterological AssociationcoreStrategic or Co-development PartnerMember organization of the Biologics Prescribers Collaborative coalition
• Clinical Neurological Society of AmericacoreStrategic or Co-development PartnerMember organization of the Biologics Prescribers Collaborative coalition
• Coalition of State Rheumatology OrganizationcoreStrategic or Co-development PartnerMember organization of the Biologics Prescribers Collaborative coalition
• Endocrine SocietycoreStrategic or Co-development PartnerMember organization of the Biologics Prescribers Collaborative coalition
• Rheumatology Nurses SocietycoreStrategic or Co-development PartnerMember organization of the Biologics Prescribers Collaborative coalition

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• International Federation of Pharmaceutical Manufacturers & Associations (IFPMA): Global pharmaceutical industry advocacy body engaging on biologic and biosimilar policy across jurisdictions. Comparable as a policy advocacy peer for biologics/biosimilar issues, though operating globally and representing manufacturers.
• American Medical Association (AMA): National physician advocacy organization engaging broadly on healthcare policy including drug pricing, biologic prescribing, and access. Comparable as a physician-led advocacy voice, though operating across all of medicine rather than biologics-specifically.
• Biotechnology Innovation Organization (BIO): Largest U.S. biotechnology industry trade association, with significant policy advocacy on biologics regulation, biosimilars, and reimbursement. Operates at broader industry scope but overlaps heavily on BPC's policy issues.
• Pharmaceutical Research and Manufacturers of America (PhRMA): Principal U.S. pharmaceutical industry advocacy organization with deep engagement on biologics, biosimilars, and Medicare drug pricing policy. Comparable as a major policy stakeholder, though broader in scope and manufacturer-aligned.

Direct peers

• National Pharmaceutical Council (NPC): Policy-focused research organization that convenes stakeholders around biopharmaceutical policy, value, and access. Comparable in operating as a non-commercial policy education and convening body in the pharmaceutical/biologic space.
• Alliance for Patient Access: Co-convener of the Biologics Prescribers Collaborative, founded by David Charles, MD. Operates a closely aligned patient-access advocacy mission focused on clinician-administered medicines and biologics, sharing leadership, infrastructure, and policy positioning.
• Biosimilars Forum: U.S. biosimilar-industry advocacy coalition focused on expanding biosimilar uptake through policy engagement. Directly comparable mission scope and policy advocacy model, though representing manufacturers rather than prescribers.
• Association for Accessible Medicines (AAM): Industry trade association representing generic and biosimilar manufacturers in U.S. policy debates. Operates on the opposite side of some policy questions BPC engages on (e.g., biosimilar uptake, interchangeability), making it a directly comparable policy advocacy peer.

Regional players

• Generics and Biosimilars Initiative (GaBI): European-headquartered information and policy hub on generics and biosimilars. Comparable in producing educational resources and policy analysis on biosimilars, though operating primarily outside BPC's U.S. geographic scope.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/bioprescribers

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biologics Prescribers Collaborative